“…Before moving on to the discussion of LC biosensors for diagnostic applications, it might be helpful to the reader if we recapitulate the pioneering works that laid the foundation of biomedical interfaces for clinical applications. For the first time, Abbott et al demonstrated that biological lipids can be self-assembled at the aqueous interfaces of LCs, resulting in phospholipid-decorated LC interfaces wherein the mobility of adsorbed lipids is comparable to that of biological membranes. ,, These studies were instrumental in designing membrane mimics to delineate complex lipid–protein interactions which play a significant role in modulating disease states. ,− These interfaces could report real-time enzymatic activity, membrane disruption of antimicrobial peptides, membrane-induced aggregation of amyloid peptides, ligand–receptor binding, and so on. ,− LCs have recently been used to construct functional interfaces for detecting environmental pollutants, small-molecule analytes, toxic metal ions, and disease-causing pathogens. − ,− Using analyte-specific recognition elements such as aptamers and antibodies, highly sensitive multiplexed detection of antigens and biomarkers has been achieved for point-of-care diagnostics. − However, although optical approaches might be more sensitive than electrochemical ones, most end users are turned off by their expense and complexity.…”